Literature DB >> 30501426

The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders.

Anna Haduch1, Władysława Anna Daniel1.   

Abstract

The current state of knowledge indicates that the cerebral cytochrome P450 (CYP) plays an important role in the endogenous metabolism in the brain. Different CYP isoenzymes mediate metabolism of many endogenous substrates such as monoaminergic neurotransmitters, neurosteroids, cholesterol, vitamins and arachidonic acid. Therefore, these enzymes may affect brain development, susceptibility to mental and neurodegenerative diseases and may contribute to their pathophysiology. In addition, they can modify the therapeutic effects of psychoactive drugs at the place of their target action in the brain, where the drugs can act by affecting the metabolism of endogenous substrates. The article focuses on the role of cerebral CYP isoforms in the metabolism of neurotransmitters, neurosteroids, and cholesterol, and their possible involvement in animal behavior, as well as in stress, depression, schizophrenia, cognitive processes, learning, and memory. CYP-mediated alternative pathways of dopamine and serotonin synthesis may have a significant role in the local production of these neurotransmitters in the brain regions where the disturbances of these neurotransmitter systems are observed in depression and schizophrenia. The local alternative synthesis of neurotransmitters may be of great importance in the brain, since dopamine and serotonin do not pass the blood-brain barrier and cannot be supplied from the periphery. In vitro studies indicate that human CYP2D6 catalyzing dopamine and serotonin synthesis is more efficient in these reactions than the rat CYP2D isoforms. It suggests that these alternative pathways may have much greater significance in the human brain but confirmation of these assumptions requires further studies.

Entities:  

Keywords:  Brain cytochrome P450; behavior; cholesterol; cognition; depression; dopamine; learning and memory; neurosteoids; schizophrenia; serotonin

Mesh:

Substances:

Year:  2019        PMID: 30501426     DOI: 10.1080/03602532.2018.1554674

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  6 in total

1.  Sex steroid hormones differentially regulate CYP2D in female wild-type and CYP2D6-humanized mice.

Authors:  Maria Konstandi; Christina E Andriopoulou; Jie Cheng; Frank J Gonzalez
Journal:  J Endocrinol       Date:  2020-05       Impact factor: 4.286

Review 2.  Alterations of Cytochrome P450s and UDP-Glucuronosyltransferases in Brain Under Diseases and Their Clinical Significances.

Authors:  Yun Sheng; Hanyu Yang; Tong Wu; Liang Zhu; Li Liu; Xiaodong Liu
Journal:  Front Pharmacol       Date:  2021-04-21       Impact factor: 5.810

3.  Differential gene expression analysis following olfactory learning in honeybee (Apis mellifera L.).

Authors:  Muhammad Fahad Raza; Muhammad Anwar; Arif Husain; Muhmmad Rizwan; Zhiguo Li; Hongyi Nie; Pavol Hlaváč; M Ajmal Ali; Ahmed Rady; Songkun Su
Journal:  PLoS One       Date:  2022-02-09       Impact factor: 3.240

4.  Biogenic amine neurotransmitters promote eicosanoid production and protein homeostasis.

Authors:  Kishore K Joshi; Tarmie L Matlack; Stephanie Pyonteck; Mehul Vora; Ralph Menzel; Christopher Rongo
Journal:  EMBO Rep       Date:  2021-01-20       Impact factor: 8.807

5.  In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions.

Authors:  Jacek Wójcikowski; Przemysław J Danek; Agnieszka Basińska-Ziobroń; Renata Pukło; Władysława A Daniel
Journal:  Pharmacol Rep       Date:  2020-03-26       Impact factor: 3.024

6.  Long-Term Treatment with Atypical Antipsychotic Iloperidone Modulates Cytochrome P450 2D (CYP2D) Expression and Activity in the Liver and Brain via Different Mechanisms.

Authors:  Przemysław J Danek; Władysława A Daniel
Journal:  Cells       Date:  2021-12-09       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.